{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:52:18Z","timestamp":1791982338561,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.amjcard.2026.08.028","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:48:30Z","timestamp":1788364110000},"page":"80-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interpreting Real-World Cardiovascular Outcomes With GLP-1 Receptor Agonists"],"prefix":"10.1016","volume":"278","author":[{"given":"Usman Ali","family":"Akbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Balla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.08.028_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2026.06.028","article-title":"Clarifying analysis inconsistencies in a study of GLP-1RAs and cardiovascular outcomes in nondiabetic patients with atherosclerotic disease and obesity","volume":"275","author":"Wang","year":"2026","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2026.05.004","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with atherosclerotic cardiovascular disease and obesity without diabetes","volume":"272","author":"Akbar","year":"2026","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0003","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0004","unstructured":"U.S. Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. FDA News Release. Published March 8, 2024. Accessed August 12, 2026.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled glucagon-like peptide-1 receptor agonists among United States adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0006","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1111\/dom.70054","article-title":"Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: a target trial emulation study","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0007","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0008","article-title":"An introduction to competing risks in epidemiology","volume":"18","author":"S\u00f8rensen","year":"2026","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.amjcard.2026.08.028_bib0009","unstructured":"TriNetX. Best practices in study design and publishing using TriNetX: advanced analytics\u2014competing risks. Available at: https:\/\/sc-ctsi.org\/uploads\/resources\/Study-Design-Publishing-Strategy-Guide.pdf. Accessed on August 1, 2026."},{"key":"10.1016\/j.amjcard.2026.08.028_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2026.100536","article-title":"Five-year competing-risk analysis of infectious and noninfectious complications after lung transplantation: real-world evidence from a multicenter EHR-based cohort","volume":"12","author":"Contreras","year":"2026","journal-title":"JHLT Open"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926005436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926005436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:32:33Z","timestamp":1791981153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926005436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"alternative-id":["S0002914926005436"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.08.028","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interpreting Real-World Cardiovascular Outcomes With GLP-1 Receptor Agonists","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.06.028","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}